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Abstract 
A cDNA clone (AF3) encoding the ubiquitin A gene 52 amino acid extension fusion protein (UbA52) was isolated from a subtracted 
cDNA library of human colorectal carcinoma minus adjacent normal mucosa. In Northern hybridization the mRNA signal for UbA52 was 
greater in surgical samples of colonic carcinoma (T) than in paired adjacent normal (N) tissues in 24 of 29 cases (T/N = 3.4 k 0.5, 
P < 0.01). An oligonucleotide probe specific for only the 52 amino acid extension confirmed the overexpression of UbA52. In contrast, 
there was no overexpression of UbA52 mRNA in gastric cancer samples (n = 7, T/N = 1.0 f 0.3). The mRNA of several ribosomal 
proteins, and of another ubiquitin A gene fusion protein, UbA80, with an 80 amino acid extension of ribosomal protein S27a, have been 
reported to be over-expressed in colon cancer, but not as yet at the protein level. Using rabbit antisera to the ribosomal protein component 
S27a we demonstrate over-expression of S27a at the protein level in colonic (n = 5), but not gastric (n = 6) carcinomas. Therefore it is 
likely that both UbA80 and UbA52 are overexpressed in colon cancer, but not in gastric cancer. 
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1. Introduction 
Subtractive or differential hybridization techniques have 
been used to isolate several gene products which are 
overexpressed at the mRNA level in colon cancer [l-6]. 
Conversely, these techniques have also detected several 
Abbreviations: rp, ribosomal protein(s); cDNA, complementary DNA; 
PCR, polymerase chain reaction; T, tumor tissue sample; N, normal 
adjacent tissue sample from the same patient; UbA52, ubiquitin-52 amino 
acid ribosomal fusion protein; UbASO, ubiquitin-80 amino acid ribosomal 
protein S27a fusion protein. 
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genes whose expression is lost in colon adenomas [7], 
cancers [8] and metastases [9]. The subject of this report is 
a clone AF3 which encodes the ubiquitin fusion protein 
UbA52. This clone was isolated from a colon tumor minus 
normal subtracted cDNA library by subtractive cDNA 
hybridization, and its mRNA is overexpressed in colon 
cancer. The ubiquitin genes encode a highly conserved 76 
amino acid peptide with two, or more [IO], structural 
arrangements, one a polyubiquitin tandem repeat [I I], the 
other arrangement is as fusion proteins with either the 80 
amino acid ribosomal protein S27a [ 121, also called UbA80, 
or a 52 amino acid ribosome-like protein [13,14], this 
fusion protein is also called UBA52. These fusion proteins 
are processed to remove ubiquitin before maturation of the 
ribosome. The UbA52 fusion protein has been cloned from 
a human placental source [ 151, and its gene localizes to 
chromosome 19p [ 161. The ubiquitin ribosomal fusion 
protein UbA52 has been cloned from a colon cancer cell 
line and its mRNA is overexpressed in human colon 
cancers [ 171. We believe no determination has yet been 
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made of an overexpression in malignancy of any ribosomal 
protein or fusion protein at the protein level. 
We report here (1) the isolation of UbA52 from a 
subtracted cDNA library of human colon cancer minus 
normal mucosa, (2) UbA52 mRNA overexpression in colon 
cancer, (3) overexpression of rp S27a at the protein level 
in colon cancer, (4) the absence of overexpression of these 
mRNAs and proteins in human gastric cancer. Parts of this 
work have been published in abstract form [ 18,191. 
2. Methods and materials 
2. I. Tissue specimens 
Surgical specimens were obtained from the New Eng- 
land Deaconess Hospital Department of Surgery as previ- 
ously described [5]. Normal colonic mucosa and normal 
gastric mucosa were dissociated from muscle and connec- 
tive tissue, as applicable, before freezing the samples 
rapidly in liquid nitrogen. 
2.2. Extraction of total RNA and Northern blot hybridiza- 
tion 
Total cellular RNA was extracted from surgical speci- 
mens or cell lines according to published methods [20,21]. 
The amount of mRNA in each sample was first compared 
by dot-blot analysis with a poly-T probe labeled with 
[ (Y- 32 P]dTTP as detailed [22]. For Northern blot hybridiza- 
tion, equal amounts (15 pg) of total cellular RNA were 
electrophoresed in 1.2% agarose-formaldehyde gels. RNA 
was transferred to GeneScreen Plus nylon filters (DuPont, 
Boston, MA) [23]. Only those filters or T/N samples with 
similar amounts of intact mRNA on dot-blot hybridization 
and with visually similar intensities of non-degraded 28s 
and 18s rRNA under UV illumination were used to calcu- 
late density ratios. Filters were pre-hybridized, hybridized, 
washed and exposed as outlined [21]. For the generation of 
probes, cDNA inserts were cut from clones of interest 
using XbaI/HindIII or XhoI/SacI endonuclease diges- 
tion. Clones coding a partial sequence of p-actin [24], or 
glyceraldehyde-3-phosphate dehydrogenase (Clontech, Palo 
Alto, CA), transforming growth factor alpha, or a trans- 
forming growth factor beta inducible gene (Shideng Bao, 
unpublished observations) were used as internal controls as 
indicated. The inserts and PCR products were purified by 
agarose gel electrophoresis, recovered using Geneclean 
(Bio 101, La Jolla, CA), or Qiaex purification (Qiagen, 
Chatsworth, CA) and labeled with [ a-32P]dCTP (30 FCi, 
800 Ci/mmol) using a random primed DNA labeling kit 
(Boehringer Mannheim, Indianapolis, IN). Specific activi- 
ties of the probes were w 2.5 . IO* cpm/pg DNA. Hy- 
bridization signals were quantitated by an LKB Ultroscan- 
ner XL enhanced laser densitometer (LKB Produkter AB, 
Bromma, Sweden) and analyzed by computer using the 
LKB 2400 GelScan XL software package. The integrated 
areas under the density curves produced the tumor/normal 
ratios as an estimate of mRNA expression. 
2.3. cDNA library generation and isolation of clone AF3 
encoding UbA52 
A plasmid oligo-(dT) primed subtraction cDNA library 
representing differentially expressed gene products was 
prepared as described [5] from primary colorectal carci- 
noma minus normal adjacent mucosa. Screening N 2200 
colonies with inserts by +/- hybridization was per- 
formed as described [5]. This yielded clones, including 
AF3 encoding ubiquitin-52, which had consistent T > N 
expression upon repeated plating and hybridization. Clone 
AF3 had a 524 bp insert which had 99.8% nucleotide 
homology, over a 501 bp overlap, with human placental 
UbA52 amino acid fusion protein [15]. A 154 bp cDNA 
probe specific for the 52 amino acid extension of UbA52 
was generated by PCR amplification using the insert of 
clone AF3 as template and primers derived from the 
sequence of UbA52 [ 151, 5’-ATTATTGAGCCT- 
TCTCTCGCCAGC-3’ and T-TGACCTTCTTCTTGG- 
GACGCAGG-3’. 
2.4. Immunohistochemical staining for rp S27a 
Antisera to the larger protein formed with ubiquitin (in 
UbASO), and identified as ribosomal protein S27a in rat, 
were prepared using a synthetic peptide (cys-tyr-lys-val- 
asp-glu-asn-gly-lys-ile-ser-arg-leu-arg) corresponding to 
residues 30-42 of the human sequence. The amino termi- 
nal cysteine is not part of the natural protein, but was used 
to couple the peptide to a carrier protein prior to injection 
into rabbits. The details of the peptide synthesis and 
antibody preparation have been previously reported [25]. 
Immunohistochemical studies were performed on 5 cases 
of colorectal carcinoma and 6 cases of gastric carcinoma 
and their respective grossly normal adjacent tissues. Tis- 
sues were fixed in 10% neutral buffered formalin and then 
embedded in paraffin. Serial 5 pm thick sections were cut 
from each block. One section was stained with hema- 
toxylin and eosin and another was mounted on poly-L- 
lysine coated slides for immunohistochemical staining for 
S27a. The normal tissue was cut from the anal margin of 
the resected colon specimen, it was at least 5 cm away 
from the tumor tissue. The endogenous peroxidase activity 
was blocked with 3% hydrogen peroxide in 100% methanol 
for 30 min. Sections were then rinsed in phosphate-buffered 
saline, incubated with normal goat serum for 30 min, and 
incubated in humid chambers with the primary antibody, 
rabbit anti-human rp S27a, diluted 1:200, for 1 h at room 
temperature. This was followed by immunoperoxidase 
staining using avidin-biotin-peroxidase complex kits (Vec- 
tor Laboratories, Burlingame, CA). The immunostaining 
was developed by 0.01% hydrogen peroxide and 0.05% 
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diaminobenzidine tetrahydrochloride for 2 min. After a 
light counterstaining with Methyl green, the sections were 
mounted. Negative controls substituted rabbit normal serum 
for the primary antibody, and they were always negative. 
3. Results 
3.1. Northern blot analysis of RNA from colon and gastric 
carcinomas probed with UbA52 cDNA 
The UbA80 fusion protein mRNA is overexpressed in 
colon cancer, [17]. Clone AF3 was isolated from a tumor 
minus normal colon cancer subtracted cDNA library and 
found to encode UbA52 not the UbA80 fusion protein 
isolated in our laboratories from a colon cancer cell line. In 
Northern hybridization studies, the mRNA signal for AF3 
was greater in surgical samples of colonic carcinoma (T) 
than in paired adjacent normal (N) tissues in 24 of 29 
cases (T/N = 3.4 f 0.5, P < 0.011, data not shown. This 
is to be expected since UbA80 mRNA has been reported to 
be overexpressed in colon cancer [17] and a probe for 
UbA80, or UbA52 or even ubiquitin alone should detect 
the ‘comigrating’ transcripts from these two fusion pro- 
teins [ 151. In contrast to these results with colon cancer, 
there was no overexpression of ubiquitin mRNA in gastric 
cancer samples (n = 7, T/N = 1.0 + 0.31, Fig. 1A. 
Human cells contain 3 classes of ubiquitin-specific 
mRNA (UbA, UbB and UbC) that are N 650, 1100 and 
2500 nucleotides long, respectively [l I]. The relative 
amounts of these 3 size classes of RNA are reportedly 
about the same in different tissues from the same species, 
in humans UbA RNA is the most abundant [l 11. Of note, 
whereas in intestinal mucosa there were strong signals for 
UbB and UbC, in a human gastrinoma there were only 
barely detectable signals from UbB and UbC [ll]. The 
ratio of signal strength between UbA, UbB and UbC 
differed somewhat between our colon and gastric samples. 
UbB from both colon and gastric samples gave the weak- 
est signal (compared to UbA and UbC). The UbC hy- 
bridization signal from metastatic and primary colon can- 
cer and adjacent normal samples, all from the same pa- 
tient, gave a weaker UbC signal (compared to UbA, Fig. 
1B) whereas UbC and UbA had similar intensities in the 
gastric samples (Fig. 1A). 
The 52 amino acid extension of UbA52 is fused to 
ubiquitin A and not UbB or UbC. A probe specific to the 
52 amino acid extension of UbA52 was generated by PCR 
amplification from clone AF3. In Northern hybridization 
with colon cancer samples the expected tumor overexpres- 
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Fig. I. Northern blot analysis of total RNA from gastric and colon cancer samples probed with UbA52 cDNA. Total RNA (15 fig) was fractionated by 
electrophoresis on 1.2% agarose formaldehyde gels and transferred to nylon membranes. Paired surgical samples (T = tumor, N = normal adjacent 
mucosa) were probed with “P-labeled cDNA encoding human UbA52, or a probe specific for the _52-amino acid extension of UbA52, control 
hybridization’s of the same filters used elongation factor I-alpha (EFl a), p-actin or glyceraldehyde-3-phosphate dehydrogenase (GPDH) probes. The 
position of 18s rRNA is shown. UbA, monomeric ubiquitin A gene; UbB, polybiquitin B gene; UbC, polyubiquitin C gene. (A) Gastric cancer and 
adjacent normal mucosa (n = 7 pairs). (B) Metastatic colon cancer to liver (TL), adjacent normal liver (NL), primary colon cancer (TC) or adjacent normal 
colonic epithelium (NC), samples from the same patient. (C) Colon cancer and adjacent normal tissue (n = 3 pairs) probed with a cDNA probe specific for 
the 52-amino acid extension of UbA52. 
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Fig. 2. Northern blot analysis of total RNA from gastric cancer samples probed with a transforming growth factor beta inducible gene and of normal tissues 
probed with UbA52 cDNA. Total RNA (15 Fg) was fractionated by electrophoresis on 1.2% agarose formaldehyde gels and transferred to nylon 
membranes. (A) Seven pairs of gastric cancer samples (T = tumor, N = normal adjacent mucosa) were probed with s* P-labeled cDNA encoding a 
transforming growth factor beta inducible gene (TGF) and then with glyceraldehyde-3-phosphate dehydrogenase (GPDH). The positions of 28s rRNA and 
18s rRNA are shown. B, RNA from normal tissues, 15 pg of each, L = liver, G = gastric mucosa, C = colon mucosa probed with a cDNA probe specific 
for the 52-amino acid extension of UbA52 and then with glyceraldehyde-3-phosphate dehydrogenase (GPDH). The position of 18s rRNA is shown. 
sion of the mRNA for UbA52 was detected with this probes. As predicted, there was no signal from the higher 
52-only probe (Fig. lC> in 8/l 1 samples, similar to the molecular weight regions of UbB and UbC when this 
overexpression detected with the UbA52 and UbA80 probe, specific to the amino acid extension, was used. 
Fig. 3. Immunohistochemical staining of human colon cancer for rp S27a. Human colorectal carcinoma sections were stained with rabbit antisera to t-p 
S27a. the 80 amino acid extension of UbASO. Positive staining is noted more in the cancerous elements (lower, arrow) than the adjacent normal cells 
(upper half). Magnification X 92, bar represents 0.1 mm. 
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The mRNA for UbA52 was not overexpressed in any of 
the gastric cancer tumor/normal samples (Fig. 1A). As a 
control, mRNA from the gastric cancer samples was probed 
with transforming growth factor alpha, a gene which is 
overexpressed at the mRNA level in N 50% of gastric 
cancers, and with a transforming growth factor beta in- 
ducible gene. These probings gave a variable result be- 
tween different gastric cancer samples, with marked over- 
expression in two of the tumor samples, and a much lower 
expression than in the paired normals in two other tumor 
samples (Fig. 2A). The steady state level of UbA52 mRNA 
was similar between normal liver, normal gastric mucosa 
and normal colonic mucosal samples (Fig. 2B). 
3.2. Protein staining of colon and gastric carcinomas with 
rp S27a antisera 
Rabbit polyclonal antisera were used to immunohisto- 
chemically stain sections from human colon and gastric 
carcinomas. In colon carcinoma, staining of the cytoplasm 
was markedly increased as compared to the normal mu- 
cosa in all five cases tested, Fig. 3. Staining of the gastric 
carcinoma sections was variable between different samples 
(not shown). Three gastric tumor samples had staining 
equal to normal, two had tumor less than normal and one 
of six had greater staining in the tumor than in the adjacent 
mucosa. 
4. Discussion 
In this work we demonstrate that steady state UbA52 
mRNA levels are higher in human colon cancer tissue than 
in the adjacent grossly normal tissue and that the protein 
expression of another ribosomal component (S27a) of 
UbA80, is greater in colon cancer than in the adjacent 
normal mucosa. This extends previous observations that 
certain ribosomal protein mRNAs are overexpressed in 
colon cancer [l-5,17,26], and in other tumors including 
breast carcinoma [27,28]. The increased expression of se- 
lected rp mRNAs is not specific for malignancy but has 
been noted in premalignant adenomas [3]. The mechanism 
and reason for the increased expression of these ribosomal 
protein mRNA’s in colon cancer, and for that of the 
ubiquitin fusion proteins demonstrated here, is unknown, 
some general possibilities have been discussed previously 
for ribosomal proteins L18 and L37 [29]. In normal tissues 
ribosomal protein synthesis may be increased by increas- 
ing the efficiency of translation without alterations in 
mRNA levels, here we observe increased steady state 
mRNA levels. It is unlikely that the increased mRNA 
expression in colon cancer is due simply to a higher 
percentage of dividing cells within the tumor. The turnover 
time in colon cancer may not be significantly different 
from that of ‘normal’ colonic mucosa[30,31] which has a 
high basal proliferation rate. It has however been sug- 
gested that the entire nonmalignant colon of patients with 
colon cancer may have an elevated proliferation rate, 
compared to normal populations [32,33]. The increased 
T/N ratios for rp mRNA’s for individual cancer patients 
might therefore underestimate the extent of overexpression 
if compared to truly normal colons. However, such a 
comparison would introduce inter-patient variability. An 
increase in growth rate does not necessarily increase rp 
mRNA levels. In both quiescent and proliferating human 
fibroblasts or peripheral blood mononuclear cells, rp 
mRNA levels were not increased by serum or mitogen 
stimulation [34]. Conversely, in ras-transformed PA-l cells 
the level of rp S2 mRNA expression was markedly in- 
creased, compared to untransformed PA-l cells, under 
conditions in which the growth rates were selected to be 
similar [27]. The rps involved in increased mRNA expres- 
sion vary for different histologic types of tumor. The same 
rp mRNA’s which were increased in colon cancer (S6, 
L18, L37, PO) were not increased in gastric carcinoma 
samples [29]. Similarly, we demonstrate here that a fusion 
protein with a ribosomal element, UbA52 mRNA, is over- 
expressed in colon cancer but not in gastric cancer. It is 
hard to explain why two gastrointestinal tract cancers, 
colon cancer and gastric cancer do, and do not, respec- 
tively, have overexpression of these rp’s if the increase is a 
general nonspecific effect related to the malignant state or 
to a nonspecific effect of growth or proliferation rate. Only 
one of several rp mRNA’s (PO) was elevated in hepato- 
cellular carcinomas [5,29]. PO mRNA is markedly overex- 
pressed in cell lines which are deficient in a DNA repair 
activity [35], and PO has homology to a DNA repair 
enzyme [36], thus it is possible that PO overexpression 
could be more related to a potential DNA repair activity 
than to a ribosomal constituent function. Ribosomal pro- 
teins may play some role in several malignancies, for 
example, the N-terminal portion of rp L7a is fused to the 
tyrosine kinase domain of the protooncogene trk, [37]; rp 
S6 may be important in melanotic tumor suppression [38]; 
and the gene encoding rp L22 is the target of a chromoso- 
ma1 translocation in some leukemias [39] leading to the 
suggestion that rp L22 levels may be a determinant in cell 
transformation [40]. 
Ubiquitin is involved in DNA replication, the stress 
response and in cell cycle control, e.g., [41], it occurs both 
free and covalently attached to a variety of receptors at its 
C-terminal end to target the attached protein for a range of 
fates. There is no direct evidence that ubiquitin genes may 
be important in malignancy, but some comments can be 
made, (1) the yeast DNA repair gene RAD6 encodes a 
ubiquitin conjugating enzyme [42] and genes implicated in 
hereditary nonpolyposis colorectal cancer encode DNA 
repair enzymes, e.g., [43]; (2) the yeast DOA gene en- 
codes a de-ubiquitinating enzyme related to the human 
tre-2 oncogene [44]; (3) ubiquitin genes are expressed at 
high levels in hematopoietic malignant tumor cells [45]; 
(4) rapid degradation of the tumor suppressor gene ~53 is 
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mediated by ubiquitination, e.g., [46]; (5) the UbA80 fu- 
sion protein has been cloned from a human colon cancer 
cell line [47], its mRNA is overexpressed in colon cancers 
[17], and the gene is inducible by serum or mitogen 
stimulation, and follows the kinetics of early growth re- 
sponse genes such as c-for and c-&n 1471. 
The determination that several rp mRNAs are overex- 
pressed in colon cancer has been based on Northern RNA 
hybridization and in situ RNA hybridization studies, e.g., 
[26,27]. We have determined here that this extends to the 
protein level for rp S27a based on immunohistochemical 
staining. The overexpression of a ubiquitin fusion protein 
mRNA or protein in colon cancer did not extend to another 
gastrointestinal malignancy gastric cancer. One cannot dis- 
tinguish in prior studies [17,47], based on Northern blots 
using ubiquitin-containing probes, whether the mRNA 
which was overexpressed in colon cancer actually derived 
from the 80 amino acid rp S27a or from the -52 fusion 
proteins or both, because their respective mRNA’s co- 
migrate [ 151. However, since our AF3 clone encoding 
UbA52 was isolated from a colon tumor minus normal 
subtracted cDNA library, and since the mRNA overexpres- 
sion was verified using a probe based on the 52 amino acid 
extension only, then it is likely that UbA52 is overex- 
pressed. Furthermore, since we have shown that rp S27a is 
overexpressed at the protein level it is likely that UbA80 is 
also overexpressed in colon cancer. 
In summary, the UbA52 fusion protein has been iso- 
lated from a subtracted cDNA library of human colon 
cancer, it’s mRNA is overexpressed in colon cancer but 
not gastric cancer. Overexpression of UbA80 fusion pro- 
tein is likely at the protein level in colon cancer since the 
80 amino acid rp S27a component is overexpressed, as 
determined immunohistochemically. This we believe rep- 
resents the first demonstration of overexpression of a 
selected ribosomal protein, in colon cancer, at the protein 
level. Since UbA80 mRNA levels of expression may corre- 
late with stage of colorectal cancer [17], immunohisto- 
chemical protein staining for rp S27a might prove useful 
prognostically. 
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